COMMUNIQUÉS West-GlobeNewswire

-
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
20/05/2025 -
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
20/05/2025 -
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
20/05/2025 -
INVO Fertility Announces First Quarter 2025 Financial Results
20/05/2025 -
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
20/05/2025 -
PCI BIotech: Disclosure of voting rights for Chair of the Board
20/05/2025 -
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
20/05/2025 -
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie
20/05/2025 -
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
20/05/2025 -
CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet
20/05/2025 -
Neuphoria Provides First Quarter 2025 Business Updates
20/05/2025 -
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
20/05/2025 -
TrialWire the AI and Algorithm-powered Platform Named a Fierce CRO Award Finalist in the “Outstanding Patient Recruitment and Retention” Category
20/05/2025 -
Global Alzheimer’s Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer’s Disease
20/05/2025 -
Segra International Acquires Klonetics to Expand Nursery Capacity and Accelerate Growth
20/05/2025 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/05/2025 -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/05/2025 -
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20/05/2025 -
MedX Holdings, Inc. (OTC: MEDH) Announces Record Q1 2025 Revenue and Strategic Advances Across Cannabis, Retail Tech, and Franchise Growth
20/05/2025
Pages